This rating reflects Lupin's leadership in environmental transparency and performance
In 2023, Endox had revenues of approximately SEK 65 million
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Subscribe To Our Newsletter & Stay Updated